Health
Novartis Lifts Outlook on Growth in Cancer, Psoriasis Drugs
This article is for subscribers only.
Novartis AG raised its outlook for the year after profit beat estimates in the first quarter, driven by medicines for breast cancer, multiple sclerosis and psoriasis.
Core operating profit will likely grow by a low double-digit percentage and sales by a high-single digit one, the Swiss drugmaker said Tuesday. In January it gave a broader growth band.